Skip to main content

Sutro Biopharma, Inc.

STRO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001382101

No open-market purchases or sales by Sutro Biopharma, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $545.7M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Sutro Biopharma, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of STRO: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders10188−13
Shares55.5M53.4M−2.14M (−3.9%)
Value$39.6M$46.4M+$6.72M (+16.9%)

New holders (10)

Institutions that held Sutro Biopharma, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to STRO in Q3 2025
InstitutionSharesValue% of portfolio
Jacobs Levy Equity Management, Inc445,750$387.1K0.00%
Gsa Capital Partners LLP174,843$152.0K0.01%
Bluefin Capital Management, LLC34,934$30.3K0.01%
XTX Topco Ltd19,131$16.6K0.00%
FNY Investment Advisers, LLC10,000$8.00K0.00%
SRS Capital Advisors, Inc.3,843$3.34K0.00%
Rockefeller Capital Management L.P.2,365$2.05K0.00%
Bare Financial Services, Inc549$4770.00%
Jones Financial Companies LLLP250$2220.00%
Advisory Services Network, LLC147$1280.00%

Sold out (23)

Institutions that held Sutro Biopharma, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.